Ribaudo, Heather J <br/><br/>
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.  [electronic resource] 

 -  The Journal of infectious diseases  Sep 2010 
 - 717-22 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1537-6613 
<br/><br/><label>Standard No.: </label>10.1086/655470  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B<br/>ATP Binding Cassette Transporter, Subfamily B, Member 1--genetics<br/>Alkynes<br/>Anti-HIV Agents--pharmacokinetics<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Benzoxazines--pharmacokinetics<br/>Black People<br/>Cyclopropanes<br/>Cytochrome P-450 CYP2B6<br/>Cytochrome P-450 CYP3A--genetics<br/>Female<br/>HIV Infections--drug therapy<br/>Hispanic or Latino<br/>Humans<br/>Male<br/>Oxidoreductases, N-Demethylating--genetics<br/>Pharmacogenetics<br/>Polymorphism, Single Nucleotide<br/>Reverse Transcriptase Inhibitors--pharmacokinetics<br/>Treatment Outcome<br/>White People